Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin

Journal of Clinical Pharmacology

Volumn 54, Issue 6, 2014, Pages 649-656

  Custodio, Joseph M ^a   Wang, Hui ^a   Hao, Jia ^a   Lepist, Eve Irene ^a   Ray, Adrian S ^a   Andrews, Jessica ^a   Ling, Kah Hiing J ^a   Cheng, Andrew ^a   Kearney, Brian P ^a   Ramanathan, Srinivasan ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

breast cancer resistance protein; elvitegravir; organic anion transporting polypeptide; pharmacokinetics; statins; Stribild

Indexed keywords

ATAZANAVIR; BREAST CANCER RESISTANCE PROTEIN; COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B1; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B3; POLYPEPTIDE; RITONAVIR; ROSUVASTATIN; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CARBAMIC ACID DERIVATIVE; DRUG COMBINATION; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ORGANIC ANION TRANSPORTER; PYRIMIDINE DERIVATIVE; QUINOLONE DERIVATIVE; SLCO1B1 PROTEIN, HUMAN; SLCO1B3 PROTEIN, HUMAN; SULFONAMIDE; THIAZOLE DERIVATIVE; TUMOR PROTEIN;

ADULT; ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; EFFUSION; FEMALE; HUMAN; IC 50; IN VITRO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NORMAL HUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CHO CELL LINE; CLINICAL TRIAL; CRICETULUS; DOG; DRUG COMBINATION; DRUG INTERACTION; MDCK CELL LINE; METABOLISM;

ADULT; ANIMALS; ANTI-HIV AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CARBAMATES; CHO CELLS; CRICETULUS; DOGS; DRUG COMBINATIONS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MADIN DARBY CANINE KIDNEY CELLS; MALE; NEOPLASM PROTEINS; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; PYRIMIDINES; QUINOLONES; SULFONAMIDES; THIAZOLES;

EID: 84899875020     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.256     Document Type: Article

References (30)

1. Dube MP, Parker RA, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS. 2005; 19: 1807-1818.
2. Brown TT, Glesby MJ., Management of the metabolic effects of HIV and HIV drugs. Nat Rev Endocrinol. 2011; 8 (1): 11-21.
3. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and coronary heart disease evaluation (Greace) study: a post-hoc analysis. Lancet. 2010; 376: 1916-1922.
4. Chauvin B, Drouot S, Barrail-Tran A, et al. Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacokinet. 2013; 52 (10): 815-831.
5. Reyataz® US FDA, Prescribing Information. 2013.
6. Prezista® US FDA Prescribing Information. 2013.
7. Kaletra® US FDA Prescribing Information. 2013.
8. Sekar VJ, Spinosa-Guzman S, Marien K, et al. Pharmacokinetic drug-drug interaction between the new HIV protease inhibitor darunavir (TMC114) and the lipid-lowering agent pravastatin. 8th International Workshop on Pharmacology of HIV Therapy. April 16-18, 2007. Budapest. Abstract 55.
9. Busti AJ, Bain AM, Hall RG II, et al. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. J Cardiovasc Pharmacol. 2008; 51 (6): 605-610.
10. Kiser JJ, Gerber JG, Predhomme JA, et al. Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr. 2008; 47 (5): 570-578.
11. DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet. 2012; 379 (9835): 2429-2438.
12. Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012; 379 (9835): 2439-2448.
13. Molina JM, Lamarca A, Andrade-Villaneuva J, et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis. 2011; 12 (1): 27-35.
14. Ramanathan S, Mathias AA, German P, et al. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet. 2011; 50 (4): 229-244.
15. DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naïve and treatment-experienced patients. J Acquir Immune Defic Syndr. 2006; 43: 1-5.
16. German P, Warren D, West S, et al. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. J Acquir Immune Defic Syndr. 2010; 55 (3): 323-329.
17. Mathias AA, German P, Murray BP, et al. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther. 2010; 87 (3): 322-329.
18. Ramanathan S, Warren D, Wei L, et al. Pharmacokinetic boosting of atazanavir with the pharmacoenhancer GS-9350 versus ritonavir. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 12-15, 2009. San Francisco. Abstract AI-1301.
19. Mathias A, Liu HC, Warren D, et al. Relative bioavailability and pharmacokinetics of darunavir when boosted with the pharmacoenhancer GS-9350 versus ritonavir. 11th International Workshop on Clinical Pharmacology and HIV Therapy. April 7-9, 2010. Sorrento. Abstract 28.
20. Hirano M, Maeda K, Shitara Y, Sugiyama Y., Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004; 311 (1): 139-146.
21. Sasaki M, Suzuki H, Ito K, Abe T, Sugiyama Y., Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and Multidrug resistance-associated protein 2 (MRP2/ABCC2). J Biol Chem. 2002; 277 (8): 6497-6503.
22. Brown CDA, Windass A, Blessby K, Lauffart B., Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C [Abstract P174]. Atherosclerosis. 2001; 2 (suppl 2): 90.
23. Ramanathan S, Wang H, Stondell T, et al. Pharmacokinetics and drug interaction profile of cobicistat boosted-elvitegravir with atazanavir, rosuvastatin or rifabutin, 13th International Workshop on Pharmacology of HIV Therapy. April 16-18, 2012. Barcelona, Spain. Abstract O-03.
24. Lepist EI, Phan TK, Roy A, et al. Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro. Antimicrob Agents Chemother. 2012; 56 (10): 5409-5413.
25. Lipitor® US FDA Prescribing Information. 2013.
26. Kapur NK., Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease. Expert Rev Cardiovasc Ther. 2007; 5 (2): 161-175.
27. Calza L, Manfredi R, Chiodo F., Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother. 2004; 53: 10-14.
28. Annaert P, Ye ZW, Stieger B, et al. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica. 2010; 40 (3): 163-176.
29. Samineni D, Desai PB, Sallans L, et al. Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid lowering agent rosuvastatin. J Clin Pharmacol. 2102; 52 (6): 922-931.
30. Crestor® US FDA Prescribing Information. 2013.